Head And Neck Squamous Cell Carcinoma clinical trials

Explore recruiting head and neck squamous cell carcinoma clinical trials.

Recruiting head and neck squamous cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Head And Neck Squamous Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Randomized, Double-Blind, Controlled Study of XL092 in Combination With Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Slovakia, France, Romania, Greece, Poland, Bulgaria +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase II, Multicenter, Randomized Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO immuno-oncology)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Spain, Netherlands, Belgium, Poland, France, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)

Belgium, Poland, France, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants with Head and Neck Squamous Cell Carcinoma OrigAMI-4

Poland, Germany, France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Head And Neck Squamous Cell Carcinoma trials by city

Head And Neck Squamous Cell Carcinoma in Toronto Head And Neck Squamous Cell Carcinoma in Vancouver Head And Neck Squamous Cell Carcinoma in Montreal Head And Neck Squamous Cell Carcinoma in Calgary Head And Neck Squamous Cell Carcinoma in Edmonton Head And Neck Squamous Cell Carcinoma in Ottawa Head And Neck Squamous Cell Carcinoma in Winnipeg Head And Neck Squamous Cell Carcinoma in Quebec City Head And Neck Squamous Cell Carcinoma in Hamilton Head And Neck Squamous Cell Carcinoma in Kitchener Head And Neck Squamous Cell Carcinoma in London Head And Neck Squamous Cell Carcinoma in Halifax Head And Neck Squamous Cell Carcinoma in New York Head And Neck Squamous Cell Carcinoma in Los Angeles Head And Neck Squamous Cell Carcinoma in Chicago Head And Neck Squamous Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease